What question did this study set out to answer?

The research aims to evaluate the efficacy of cefepime and its beta-lactamase inhibitor combinations against drug-resistant Gram-negative bacteria.

February 10, 2026Open Access

Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics

View Full Paper

Ask AI

Bookmark

Authors

This review examines cefepime-based combinations for treating resistant Gram-negative bacteria, suggesting promising outcomes.

The research aims to evaluate the efficacy of cefepime and its beta-lactamase inhibitor combinations against drug-resistant Gram-negative bacteria.
Review of preclinical and clinical studies on cefepime-based beta-lactam/beta-lactamase inhibitor combinations
Focus on combinations such as cefepime/enmetazobactam and cefepime/taniborbactam
Analysis of activity restoration against multidrug-resistant strains
Cefepime/enmetazobactam restores activity against class A ESBLs
Cefepime/taniborbactam and cefepime/zidebactam exhibit broader inhibition
Favorable pharmacokinetic/pharmacodynamic profiles indicated
Optimal Cmax/MIC ratio of 8–10 supports cefepime/enmetazobactam efficacy
Ongoing Phase III studies to confirm efficacy in complicated infections

Carcione et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark